BRPI0316895C1 - composto, processo para a preparação do composto, composição farmacêutica e uso do composto - Google Patents

composto, processo para a preparação do composto, composição farmacêutica e uso do composto

Info

Publication number
BRPI0316895C1
BRPI0316895C1 BRPI0316895A BR0316895A BRPI0316895C1 BR PI0316895 C1 BRPI0316895 C1 BR PI0316895C1 BR PI0316895 A BRPI0316895 A BR PI0316895A BR 0316895 A BR0316895 A BR 0316895A BR PI0316895 C1 BRPI0316895 C1 BR PI0316895C1
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
tetracyclic
pharmaceutically acceptable
Prior art date
Application number
BRPI0316895A
Other languages
English (en)
Other versions
BRPI0316895B1 (pt
BR0316895A (pt
BRPI0316895B8 (pt
Inventor
Sastri Kambhampati Rama
Satya Nirogi Ramakrishna Venkata
Satya Veerabhadra Vadlamudi Rao Venkata
Jasti Venkateswarlu
Shreekrishna Shirsath Vikas
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of BR0316895A publication Critical patent/BR0316895A/pt
Publication of BRPI0316895B1 publication Critical patent/BRPI0316895B1/pt
Publication of BRPI0316895B8 publication Critical patent/BRPI0316895B8/pt
Publication of BRPI0316895C1 publication Critical patent/BRPI0316895C1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

"composto, processo para a preparação do farmacêutica, novos intermediários, processo para a preparação dos novos intermediários e uso do composto". a presente invenção refere-se a novos indolos substituídos de tetracíclicos 3-substituídos, representados pela fórmula geral (i), aos seus estereoisômeros, aos seus radio isótopos, aos seus óxidos de n, aos seus polimorfos, aos seus sais farmaceuticamente aceitáveis, aos seus solvatos farmaceuticamente aceitáveis, aos seus metabólitos bio ativos úteis e a qualquer combinação dos acima mencionados assim como aos processos para a preparação de tais compostos da fórmula geral (i, dos seus estereoisômeros, dos seus radio isótopos, dos seus óxidos de n, dos seus polimorfos, dos seus sais farmaceuticamente aceitáveis, dos seus solvatos farmaceuticamente aceitáveis, dos seus metabólitos bio ativos úteis e também inclui qualquer combinação adequada dos acima mencionados.
BRPI0316895A 2002-12-18 2003-12-16 composto, processo para a preparação do composto, composição farmacêutica e uso do composto BRPI0316895C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN951/MAS/2002 2002-12-18
IN951MA2002 2002-12-18
PCT/IN2003/000393 WO2004055026A1 (en) 2002-12-18 2003-12-16 Tetracyclic 3-substituted indoles having serotonin receptor affinity

Publications (4)

Publication Number Publication Date
BR0316895A BR0316895A (pt) 2005-10-25
BRPI0316895B1 BRPI0316895B1 (pt) 2018-07-24
BRPI0316895B8 BRPI0316895B8 (pt) 2019-09-03
BRPI0316895C1 true BRPI0316895C1 (pt) 2021-05-25

Family

ID=40848934

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0316895A BRPI0316895C1 (pt) 2002-12-18 2003-12-16 composto, processo para a preparação do composto, composição farmacêutica e uso do composto

Country Status (20)

Country Link
US (1) US7781476B2 (pt)
EP (1) EP1581538B1 (pt)
JP (1) JP4571507B2 (pt)
KR (1) KR100739987B1 (pt)
CN (1) CN100378109C (pt)
AT (1) ATE355292T1 (pt)
AU (1) AU2003292510B2 (pt)
BR (1) BRPI0316895C1 (pt)
CA (1) CA2507923C (pt)
DE (1) DE60312226T2 (pt)
DK (1) DK1581538T3 (pt)
EA (1) EA009367B1 (pt)
HK (1) HK1083840A1 (pt)
MX (1) MXPA05005808A (pt)
NO (1) NO334030B1 (pt)
NZ (1) NZ540841A (pt)
PT (1) PT1581538E (pt)
SI (1) SI1581538T1 (pt)
WO (1) WO2004055026A1 (pt)
ZA (1) ZA200504042B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
AU2004312229B2 (en) 2004-01-02 2010-05-20 Suven Life Sciences Limited Novel Indeno[2,1a]indenes and isoindolo[2,1-a]indoles
JP2008532996A (ja) * 2005-03-08 2008-08-21 スヴェン・ライフ・サイエンシズ・リミテッド 置換ベンゾチアジノインドール類の合成法
PL1919896T3 (pl) 2005-08-12 2010-05-31 Suven Life Sciences Ltd Pochodne aminoarylosulfonamidu jako funkcjonalne ligandy 5-HT6
WO2007020654A1 (en) 2005-08-16 2007-02-22 Suven Life Sciences An improved process for the preparation of losartan
ES2357584T3 (es) 2007-01-08 2011-04-27 Suven Life Sciences Limited Compuestos de 5-(heterociclil) alquil-n-(arilsulfonil)indol y su uso como ligandos de 5-th6.
WO2008136017A1 (en) 2007-05-03 2008-11-13 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
US7807705B2 (en) 2007-05-18 2010-10-05 The Ohio State University Research Foundation Potent indole-3-carbinol-derived antitumor agents
MX2010003765A (es) 2007-10-26 2010-04-30 Suven Life Sciences Ltd Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6.
JP5536781B2 (ja) 2008-09-17 2014-07-02 スヴェン・ライフ・サイエンシズ・リミテッド アリールスルホンアミドアミン化合物および5−ht6リガンドとしてのそれらの使用
WO2010032257A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
US8153680B2 (en) 2009-08-25 2012-04-10 The Ohio State University Research Foundation Alkyl indole-3-carbinol-derived antitumor agents
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
ME02843B (me) 2013-12-02 2018-01-20 Suven Life Sciences Ltd Proces za masovnu proizvodnju monohidrata 1- [(2-bromofenil)sulfonil]-5-metoksi-3-[( 4- metil- 1-piperazinil)metil]-1h-indol dimezilata
MX2017002045A (es) * 2014-08-16 2017-05-04 Suven Life Sciences Ltd Metabolito activo del dimesilato de 1-[(2-bromofenil) sulfonil]-5-metoxi-3-[(4-metil-1-piperazinil) metil]-1h-indol monohidratado y sal dimesilato dihidratado de metabolito activo.
EA202090127A1 (ru) * 2017-07-03 2020-04-15 Сувен Лайф Сайенсиз Лимитед Новые применения чистого антагониста 5-htрецептора

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489429A (en) * 1967-12-18 1970-01-13 American Home Prod 1-loweralkanoyl-3-(2-substituted ethyl)indoles
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
CA2042295A1 (fr) 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
AU646871B2 (en) 1990-06-07 1994-03-10 Astrazeneca Uk Limited Therapeutic heterocyclic compounds
SK278998B6 (sk) 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
GB9113802D0 (en) 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
GB9210400D0 (en) 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
KR940007001A (ko) 1992-09-16 1994-04-26 최승주 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제
FR2737220B1 (fr) 1995-07-24 1997-09-26 Adir Sequences nucleiques codant pour des recepteurs de la melatonine et leurs applications
JP2000026471A (ja) * 1998-07-10 2000-01-25 Nippon Soda Co Ltd 11−ホルミル−インドロ[1,2−b][1,2]ベンズイソチアゾールおよび農園芸用殺菌剤
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
MXPA01005905A (es) * 1998-12-11 2002-09-18 Univ Virginia Commonwealth Ligandos selectivos de receptores de 5-ht6.
IL130169A (en) 1999-05-27 2006-08-20 Neurim Pharma 1991 Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them
FR2799757B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1317276C (zh) * 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
CA2429605A1 (en) * 2000-11-20 2002-05-30 Scios Inc. Indol derivative and their use as inhibitors of p38 kinase
FR2821843B1 (fr) * 2001-03-12 2003-05-09 Servier Lab Nouveaux derives d'isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2003066056A1 (en) 2002-02-05 2003-08-14 Glaxo Group Limited Method of promoting neuronal growth
EP1523486B1 (en) * 2002-06-21 2007-11-07 Suven Life Sciences Limited Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
DK1537113T5 (da) * 2002-06-21 2011-01-10 Suven Life Sciences Ltd Arylalkylindoler med serotoninreceptoraffinitet anvendelige som terapeutiske midler, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
ES2425143T3 (es) * 2002-11-28 2013-10-11 Suven Life Sciences Limited N-Arilsulfonil-3-aminoalcoxiindoles

Also Published As

Publication number Publication date
PT1581538E (pt) 2007-05-31
ZA200504042B (en) 2006-01-26
EP1581538B1 (en) 2007-02-28
US7781476B2 (en) 2010-08-24
CN1729197A (zh) 2006-02-01
DE60312226D1 (de) 2007-04-12
BRPI0316895B1 (pt) 2018-07-24
KR100739987B1 (ko) 2007-07-16
JP4571507B2 (ja) 2010-10-27
NO20052909L (no) 2005-09-12
WO2004055026A8 (en) 2005-06-23
NZ540841A (en) 2008-08-29
ATE355292T1 (de) 2006-03-15
CA2507923C (en) 2010-02-02
AU2003292510B2 (en) 2009-04-23
SI1581538T1 (sl) 2007-08-31
DE60312226T2 (de) 2007-11-15
DK1581538T3 (da) 2007-06-25
CN100378109C (zh) 2008-04-02
NO20052909D0 (no) 2005-06-15
BR0316895A (pt) 2005-10-25
NO334030B1 (no) 2013-11-18
WO2004055026A1 (en) 2004-07-01
KR20050084185A (ko) 2005-08-26
US20070142398A1 (en) 2007-06-21
CA2507923A1 (en) 2004-07-01
AU2003292510A1 (en) 2004-07-09
EA009367B1 (ru) 2007-12-28
HK1083840A1 (en) 2006-07-14
BRPI0316895B8 (pt) 2019-09-03
JP2006515843A (ja) 2006-06-08
MXPA05005808A (es) 2005-09-08
EA200500994A1 (ru) 2006-02-24
EP1581538A1 (en) 2005-10-05

Similar Documents

Publication Publication Date Title
NO20052909D0 (no) Tetracyclic 3-substituted indoles having serotonin receptor affinity.
ATE401307T1 (de) N-arylsulfonyl-2-substituierte indole mit affinität zum serotonin rezeptor, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
IL155702A0 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
UY27098A1 (es) Derivados de indol
UY26511A1 (es) Bases de mannich indólicas, procedimientos para su preparación, medicamentos que contienen estos compuestos y su uso para la preparación de medicamentos
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
NO20100041L (no) Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer
BRPI0516003A (pt) composto, uso em um composto ou um éster, um sal farmaceuticamente aceitável ou um hidrato do mesmo, formulação farmacêutica, e, método para a triagem in vitro de ligandos de receptor de prostanóide seletivos
EA199800340A1 (ru) Производные пиримидина как антагонисты 5нт2с
NO20032253L (no) Piperazinylpyrazinforbindelser som antagonister av serotonin 5-HT2-reseptorer
ZA200800512B (en) Substituted tetrahydro-1H-pyrido[4,3,B]indoles as serotonin receptor agonists and antagonists
BR0009083B1 (pt) derivado de amida compreendendo um núcleo de quinazolinona, processo para a preparação de um derivado de amida, composição farmacêutica, e, uso de um derivado de amida.
SG146683A1 (en) Fused heterocyclic compounds as serotonin receptor modulators
UY27850A1 (es) Nuevos carbamatos de quinuclidina y composiciones farmacéuticas que los contienen
ATE409179T1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
ATE308522T1 (de) Opioidrezeptorantagonisten
MX2007007480A (es) Derivados de cromano y su uso como ligandos del receptor 5-ht.
WO2005033112A3 (en) Substituted indole derivatives
HN2001000059A (es) Indoles
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
HUP0303513A3 (en) Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists, their use and pharmaceutical compositions containing them
DE60236848D1 (de) 8-ä4-Ä3-(5-FLUORO-1H-INDOL-3-YL)PROPYLÜ -1-PIPERAZINYLü -2-METHYL-2H-1, 4-BENZOXAZIN-3(4H)-ON METHANESULFONAT MIT HOHER AFFINITÄT FÜR DEN DOPAMIN D2 REZEPTOR UND DEN SEROTONIN REUPTAKE SITE
AU2002223528A1 (en) New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
PT1317430E (pt) Derivados de (2-azabiciclo[2.2.1]hepta-7-il)-metanol como agonistas do receptor nocotinico de acetilcolina
DOP2001000137A (es) Indoles

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/07/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/07/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2481 DE 24/07/2018, QUANTO AO ITEM (54) TITULO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2649 DE 13-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.